Table 1.
Qualitative analysis of studies included in the systematic review.
| Study name (identifier) | Author, year | GLP-1RA + SGLT2i arm | SGLT2i arm | Other therapies | Study type | Follow-up (weeks) | Number of patients |
Population | Age (years) | Diabetes duration (years) | HbA1c | Body weight | Systolic blood pressure | Lipids | HbA1c < 7% | Rescue therapy | Hypoglycemic events |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AWARD-10 (NCT02597049) | Ludvik, 2018 | Dulaglutide QW + SGLT2i | Placebo + SGLT2i | Metformin | RCT | 24 | 424 | type 2 diabetes, HbA1c 7–9.5%, BMI ≤ 45 kg/m2 | 57.3 (9.4) | 9.4 (6.2) | x | x | x | x | x | x | x |
| DUAL IX (NCT02773368) | Philis-Tsimikas, 2019 | iDegLira QD + SGLT2i | Glargine + SGLT2i | Metformin | RCT | 26 | 420 | type 2 diabetes, HbA1c 7–11%, BMI 20–40 kg/m2 | 56.7 (10.3) | 9.6 (6.3) | x | x | x | x | x | x | |
| DURATION-8 (NCT02229396) | Jabbour, 2018 | Exenatide QW + Dapagliflozin | Placebo + Dapagliflozin | Metformin | RCT | 52 | 464 | type 2 diabetes, HbA1c 8–12% | 54.5 (9.5) | 7.3 (5.7) | x | x | x | x | x | x | |
| SUSTAIN 9 (NCT03086330) | Zinman, 2019 | Semaglutide QW + SGLT2i | Placebo + SGLT2i | Metformin, sulphonylurea | RCT | 30 | 302 | type 2 diabetes, HbA1c 7–10% | 57 (9.5) | — | x | x | x | x | x | x | x |
BMI, body mass index; GLP-1RA, glucagon-like peptide-1 receptor agonist; QD, once daily; QW, once weekly; RCT, randomized controlled trial; SGLT2i, sodium glucose cotransporter 2 inhibitor.